Advances in quantitative structureactivity relationship models of antimalarials

Expert Opinion on Drug Discovery

Volumn 5, Issue 8, 2010, Pages 751-778

  Roy, Kunal ^a   Ojha, Probir Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Antimalarial; Docking; in silico drug design; QSAR; Targets

Indexed keywords

AMODIAQUINE; AMPICILLIN; ANTIDEPRESSANT AGENT; ARTEMISININ; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHALCONE; CHLOROQUINE; CIMETIDINE; COTRIMOXAZOLE; HALOFANTRINE; MEFLOQUINE; METHOTREXATE; METRONIDAZOLE; NAPHTHOQUINONE; PHENYTOIN; PRAZIQUANTEL; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE; QUINIDINE; QUININE; SULFADOXINE; THYROXINE; TRIMETHOPRIM DERIVATIVE; UNINDEXED DRUG; ANTIMALARIAL AGENT;

ABDOMINAL PAIN; ALLERGIC REACTION; ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; BRAIN TOXICITY; CARDIOTOXICITY; CAT DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CRYSTALLURIA; DEPRESSION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GENE TARGETING; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMATOPOIESIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; ISOSPORIASIS; KERATOPATHY; MALARIA; NAUSEA; NEUROTOXICITY; PHARMACOPHORE; PLASMODIUM FALCIPARUM; PNEUMONIA; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TOXOPLASMOSIS; VOMITING; ARTICLE; BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; STRUCTURE ACTIVITY RELATION;

ANTIMALARIALS; COMPUTER SIMULATION; HUMANS; MALARIA; MODELS, BIOLOGICAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954811962     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.497812     Document Type: Review

References (125)

1. Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005;434:214-217
2. Global burden of disease: 2004 update. World Health Organization, Geneva; 2008. Available from: http://www.who. int/healthinfo/global-burden-disease/en/ index.html
3. World Malaria Report. WHO, Geneva, Switzerland; 2008. Available from: www.who.int/entity/malaria/publications/atoz/.../en/index. html
4. White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis 2008;46:172-173
5. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001;64(Suppl 1-2):97-106
6. Aguas R, White LJ, Snow RW, Gomes MG. Prospects for malaria eradication in Sub-Saharan Africa. PLoS ONE 2008;3:e1767
7. Zucker JR. Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. Emerg Infect Dis 1996;2:37-43
8. WHO. Making a difference. The World Health Report 1999. Health Millions 1999;25:3-5
9. Brito I. Eradicating malaria: high hopes or a tangible goal? Health Policy Harvard 2001;2:61-66
10. Chareonviriyaphap T, Bangs MJ, Ratanatham S. Status of malaria in Thailand. Southeast Asian J Trop Med Public Health 2000;31:225-237
11. Snow RW, Trape JF, Marsh, K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 2001;17:593-597
12. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999;353:1965-1967
13. Barnes KI, Durrheim DN, Little F, et al. Effect of artemether- lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med 2005;2:e330
14. Nyarango PM, Gebremeskel T, Mebrahtu G, et al. A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. Malar J 2006;5:33
15. Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisininbased combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007;4:e309
16. Bledsoe GH. Malaria primer for clinicians in the United States. Southern Med J 2005;98:1197-1204
17. Sturm A, Amino R, van de Sand C, et al. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 2006;313:1287-1490
18. Cogswell FB. The hypnozoite and relapse in primate malaria. Clin Microbiol Rev 1992;5:26-35
19. Laveran A. De la nature parasitaire de limpaludisme. Bull Mem Soc Med Hop Paris 1882;18:168-176
20. Afonso A, Hunt P, Cheesman S, et al. Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother 2006;50:480-489
21. de Beer TAP, Wells GA, Burger PB, et al. Antimalarial drug discovery: in silico structural biology and rational drug design. Infect Dis Drug Targets 2009;3:304-318
22. Bjelic S, Nervall M, Gutierrez-de-Teran H, et al. Computational inhibitor design against malaria plasmepsins. Cell Mol Life Sci 2007;64:2285-2305
23. Greenwood BM, Fidock DA, Kyle DE, et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008;118:1266-1276
24. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005;57:117-145
25. Marsh K. Malaria disaster in Africa. Lancet 1998;352:924
26. Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci 2004;74:1957-1972
27. Yuthavong Y. Basis for antifolate action and resistance in malaria. Microb Inf 2002;4:175-182
28. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 2003;10:357-365
29. Kongsaeree P, Khongsuk P, Leartsakulpanich U, et al. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci USA 2005;102:13046-13051
30. Cody V, Galitsky N, Luft JR, et al. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry 1997;36:13897-13903
31. Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 1997;272:3961-3966
32. Berry A, Senescau A, Lelievre J, et al. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. Trans R Soc Trop Med Hyg 2006;100:986-988
33. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone clinical trials study group. Am J Trop Med Hyg 1999;60:533-541
34. Hyde JE. Drug-resistant malaria - an insight. FEBS J 2007;274:4688-4698
35. Ubalee R, Songthammawat D, Na-Bangchang K, et al. Ex vivo blood schizontocidal activities of artemisinin derivatives against Plasmodium falciparum. South East Asian J Trop Med Public Health 1999;30:225-231
36. Gu HM, Warhurst DC, Peters W. Uptake of [3H] dihydroartemisinine by erythrocytes infected with Plasm dium falciparum in vitro. Trans R Soc Trop Med Hyg 1984;78:265-270
37. Olliaro PL, Taylor WR. Antimalarial compounds: from bench to bedside. J Exp Biol 2003;206:3753-3759
38. Guidelines for the treatment of malaria. 2nd edition. World Health Organization, Geneva; 2010. Available from: http://who.int/malaria
39. Wiesner J, Ortmann R, Jomaa H, Schlitzer M. New antimalarial drugs. Angew Chem Int Ed 2003;42:5274-5293
40. Gelb MH. Drug discovery for malaria: a very challenging and timely endeavor. Curr Opin Chem Biol 2007;11:440-445
41. Woster PM. New therapies for malaria. Ann Rep Med Chem 2003;38:203-211
42. Martin YC. Computer assisted rational drug design. In: Lilley DMJ, Dahlberg JE, editors. Methods in enzymology. Academic Press, San Diego, CA; 1991. p. 587-613
43. Debnath AK. Quantitative structure - activity relationship (QSAR) paradigm - Hansch era to new millennium. Mini Rev Med Chem 2001;1:187
44. Mason JS, Good AC, Martin EJ. 3-D pharmacophores in drug discovery. Curr Pharm Des 2001;7:567-597
45. Podlogar BL, Ferguson DM. QSAR and CoMFA: a perspective on the practical application to drug discovery. Drug Des Discov 2000;17:4
46. Fraser A, Burnell D. Computer models in genetics. McGraw-Hill, New York; 1970
47. Wold S, Eriksson L. Validation tools. In: van de Waterbeemd H, editor. Chemometric methods in molecular design. VCH, Weinheim; 1995. p. 312-317
48. Snedecor GW, Cochran WG. Statistical methods. Oxford and IBH, New Delhi; 1967
49. Debnath AK. Quantitative structure - activity relationships: a versatile tool in drug design. In: Ghose AK, Viswanadhan VN, editors, Combinatorial library design and evaluation. Marcel Dekker, New York; 2001. p. 73-129
50. Roy K. On some aspects of validation of predictive quantitative structure - activity relationship models. Expert Opin Drug Discov 2007;2:567-577
51. Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008;27:302-313
52. Roy PP, Paul S, Mitra I, Roy K. On two novel parameters for validation of predictive QSAR models. Molecules 2009;14:1660-1701
53. Mitra I, Roy PP, Kar S, et al. On further application of r2m as a metric for validation of QSAR models. J Chemometrics 2010;24:22-33
54. Golbraikh A, Tropsha A. Beware of q2. J Mol Graph Mod 2002;20:269-276
55. Shen M, Beguin C, Golbraikh A, et al. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. J Med Chem 2004;47:2356-2364
56. Avery MA, Gao F, Chong WKM, et al. Structure - activity relationships of the antimalarial agent artemisinin. 1. Synthesis and comparative molecular field analysis of C-9 analogs of artemisinin and 10-deoxoartemisinin. J Med Chem 1993;36:4264-4315
57. Nguyen-Cong V, Van Dang G, Rode BM. Using multivariate adaptive regression splines to QSAR studies of dihydroartemisinin derivatives. Eur J Med Chem 1996;31:797-803
58. Avery MA, Mehrotra S, Johnson TL, et al. Structure - activity relationships of the antimalarial agent artemisinin. 5. Analogs of 10-deoxoartemisinin substituted at C-3 and C-9. J Med Chem 1996;39:4149-4155
59. Girones X, Gallegos A, Carbo-Dorca R. Modeling antimalarial activity: application of kinetic energy density quantum similarity measures as descriptors in QSAR. J Chem Inf Comput Sci 2000;40:1400-1407
60. Roy K, Pal DK, Saha A, Sengupta C. QSAR with electrotopological state atom index: part II - antimalarial activity of dihydroqinghaosu derivatives. Indian J Chem Sect B 2001;40:587-595
61. Pinheiro JC, Ferreira MMC, Romero OAS. Antimalarial activity of dihydroartemisinin derivatives against P. falciparum resistant to meflooquine: a quantum chemical and multivariate study. J Mol Struct (Theochem) 2001;572:35-44
62. Jung M, Kim H. CoMFA of artemisinin derivatives: effect of location and size of lattice. Bioorg Med Chem Lett 2001;11:2041-2044
63. Avery MA, Alvim-Gaston M, Rodrigues CR, et al. Structure - activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using comfa and hqsar methodologies, J Med Chem 2002;45:292-303
64. Cheng F, Shen J, Luo X, et al. Molecular docking and 3-d-qsar studies on the possible antimalarial mechanism of artemisinin analogues. Bioorg Med Chem 2002;10:2883-2891
65. Avery MA, Muraleedharan KM, Desai PV, et al. Structure - activity relationships of the antimalarial agent artemisinin. 8. design, synthesis, and comfa studies toward the development of artemisinin-based drugs against Leishmaniasis and malaria. J Med Chem 2003;46:4244-4258
66. Guha R, Jurs PC. Development of QSAR models to predict and interpret the biological activity of artemisinin analogues. J Chem Inf Comput Sci 2004;44:1440-1449
67. Cardoso FJ, de Figueiredo AF, da Silva Lobato M, et al. A study on antimalarial artemisinin derivatives using MEP maps and multivariate QSAR. J Mol Model 2008;14:39-48
68. Moles P, Oliva M, Sanchez-Gonzalez A, Safont VS. A topological study of the decomposition of 6,7,8-trioxabicyclo [3.2.2]nonane induced by Fe(II): modeling the artemisinin reaction with heme. J Phys Chem B 2010;114:1163-1173
69. Roy K, Pal DK, Sengupta C. Hansch analysis of antimalarial cyclic peroxy ketals with physicochemical and electrotopological parameters. Drug Des Discov 2000;17:183-190
70. Roy K, De AU, Sengupta C. QSAR of antimalarial cyclic peroxy ketals II: exploration of pharmacophoric site using AM1 calculations. Quant Struct Act Relat 2001;20:319
71. Agrawal VK, Sharma R, Khadikar PV. QSAR studies on antimalarial substituted phenyl analogues and their Nw-oxides. Bioorg Med Chem 2002;10:1361-1366
72. Dascombe MJ, Drew MGB, Morris H, et al. Mapping antimalarial pharmacophores as a useful tool for the rapid discovery of drugs effective in vivo: design, construction, characterization, and pharmacology of metaquine. J Med Chem 2005;48:5423-5436
73. Gupta MK, Prabhakar YS. Topological descriptors in modeling the antimalarial activity of 4-(3¢,5¢-disubstituted anilino) quinolines. J Chem Inf Model 2006;46:93-102
74. Sharma P, Chhabra S, Rai N, Ghoshal N. Exploration of Rate-Limiting Conformational State for 5-[(7-Chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1¢-biphenyl]-2-ols and Nw-Oxides (Tebuquine Analogues) for Antimalarial Activity Using Molecular Shape Analysis and Molecular Field Analysis Studies. J Chem Inf Model 2007;47:1087-1096
75. Deshpande S, Solomon VR, Katti SB, Prabhakar YS. Topological descriptors in modelling antimalarial activity: N(1)-(7-chloro-4-quinolyl)-1,4-bis(3- aminopropyl)piperazine as prototype. J Enzyme Inhib Med Chem 2009;24:94-104
76. Stiefl N, Bringmann G, Rummey C, Baumann K. Evaluation of extended parameter sets for the 3D-QSAR technique MaP: implications for interpretability and model quality exemplified by antimalarially active naphthylisoquinoline alkaloids. J Comput Aided Mol Des 2003;17:347-365
77. dos Santos EVM, Carneiro JW deM, Ferreira VF. Quantitative structure - activity relationship in aziridinyl-1,4- naphthoquinone antimalarials: study of theoretical correlations by the PM3 method. Bioorg Med Chem 2004;12:87-93
78. Zahouily M, Lazar M, Elmakssoudi A, et al. QSAR for anti-malarial activity of 2-aziridinyl and 2,3-bis(aziridinyl)- 1,4-naphthoquinonyl sulfonate and acylate derivatives. J Mol Model 2006;12:398-405
79. Agrawal VK, Sinha S, Bano S, Khadikar PV. QSAR studies on antimalarial 2,4-diamino-6-quinazoline sulfonamides. Acta Microbiol Immunol Hung 2001;48:17-26
80. Agrawal VK, Srivastava R, Khadikar PV. SAR studies on some antimalarial sulfonamides. Bioorg Med Chem 2001;93:3287-3293
81. Liu M, Wilairat P, Go M. Antimalarial alkoxylated and hydroxylated chalones: structure - activity relationship analysis. J Med Chem 2001;44:4443-4452
82. Liu M, Wilairat P, Croft SL, et al. Structure - activity relationships of antileishmanial and antimalarial chalcones. Bioorg Med Chem 2003;11:2729-2738
83. Xue CX, Cui SY, Liu MC, et al. 3D QSAR studies on antimalarial alkoxylated and hydroxylated chalcones by CoMFA and CoMSIA. Eur J Med Chem 2004;39:745-753
84. Bhattacharjee AK, Nichols DA, Gerena L, et al. An in silico 3D pharmacophore model of chalcones useful in the design of novel antimalarial agents. Med Chem 2007;3:317-326
85. Begum NA, Roy N, Laskar RA, Roy K. Mosquito larvicidal studies of some chalcone analogues and their derived products: structure - activity relationship analysis. Med Chem Res 2010; doi: 10.1007/s00044-010-9305-6
86. Sivaprakasam P, Tosso PN, Doerksen RJ. Structure - activity relationship and comparative docking studies for cycloguanil analogs as PfDHFR-TS inhibitors. J Chem Inf Model 2009;49:1787-1796
87. Adane L, Bharatam PV. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme. J Mol Graph Model 2009;28:357-367
88. Kim KH, Hansch C, Fukunaga JY, et al. Quantitative structure - activity relationships in l-aryl-2-(alkylamino) ethanol antimalarials. J Med Chem 1979;22:367
89. Nguyen-Cong V, Rode BM, Quantum pharmacological analysis of structure - activity relationships for mefloquine antimalarial drugs using optimal transformations. J Chem Inf Comput Sci 1996;36:114-117
90. Calas M, Cordina G, Bompart J, et al. Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure - activity relationship analysis. J Med Chem 1997;40:3557-3566
91. Grigorov M, Weber J, Tronchet JMJ, et al. A QSAR study of the antimalarial activity of some synthetic 1,2,4-trioxanes. J Chem Inf Comput Sci 1997;37:124-130
92. Pandey SK, Naware NB, Trivedi P, Saxena AK. Molecular modeling and 3D-QSAR studies in 2-aziridinyl-and 2,3-bis(aziridinyl)-1,4-naphthoquinonyl sulfonate and acylate derivatives as potential antimalarial agents. SAR QSAR Environ Res 2001;12:547-564
93. Bhattacharjee AK, Kyle DE, Vennerstrom JL, Milhous WK. A 3D QSAR pharmacophore model and quantum chemical structure - activity analysis of chloroquine(CQ)-resistance reversal. J Chem Inf Comput Sci 2002;42:1212-1220
94. Bhattacharjee AK, Hartell MG, Nichols DA, et al. Structure - activity relationship study of antimalarial indolo [2,1-b]quinazoline-6,12-diones (tryptanthrins). Three dimensional pharmacophore modeling and identification of new antimalarial candidates. Eur J Med Chem 2004;39:59-67
95. Fontaine F, Pastor M, Sanz F. Incorporating molecular shape into the alignment-free GRid-independent descriptors. J Med Chem 2004;47:2805-2815
96. Marrero-Ponce Y, Montero-Torres A, Zaldivar CR, et al. Non-stochastic and stochastic linear indices of the molecular pseudographs atom adjacency matrix: application to in silico studies for the rational discovery of new antimalarial compounds. Bioorg Med Chem 2005;13:1293-1304 (Pubitemid 40164613)
97. Marrero-Ponce Y, Iyarreta-VeitIa M, Montero-Torres A, et al. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. J Chem Inf Model 2005;45:1082-1100
98. Mahmoudi N, de Julian-Ortiz JV, Ciceron L, et al. Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening. J Antimicrob Chemother 2006;57:489-497
99. Katritzky AR, Kulshyn OV, Stoyanova-Slavova I, et al. Antimalarial activity: A QSAR modeling using CODESSA PRO software. Bioorg Med Chem 2006;14:2333-2357
100. Montero-Torres A, Garcia-Sanchez RN, Marrero-Ponce Y, et al. Non-stochastic quadratic fingerprints and LDA-based QSAR models in hit and lead generation through virtual screening: theoretical and experimental assessment of a promising method for the discovery of new antimalarial compounds. Eur J Med Chem 2006;41:483-493
101. Xie A, Sivaprakasam P, Doerksena RJ. 3D-QSAR analysis of antimalarial farnesyltransferase inhibitors based on a 2,5-diaminobenzophenone scaffold. Bioorg Med Chem 2006;14:7311-7323
102. Cruz-Monteagudo M, Borges F, Perez Gonzalezc M, Cordeiro MNDS. Computational modeling tools for the design of potent antimalarial bisbenzamidines: overcoming the antimalarial potential of pentamidine. Bioorg Med Chem 2007;15:5322-5339
103. Garcia-Domenech R, Lopez-Pena W, Sanchez-Perdomo Y, et al. Application of molecular topology to the prediction of the antimalarial activity of a group of uracil-based acyclic and deoxyuridine compounds. Int J Pharm 2008;363:78-84
104. Prado-Prado FJ, Gonzalez-Diaz H, de la Vega OM, et al. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg Med Chem 2008;16:5871-5880
105. Mahmoudi N, Garcia-Domenech R, Galvez J, et al. New active drugs against liver stages of Plasmodium predicted by molecular topology. Antimicrob Agents Chemother 2008;52:1215-1220
106. Rodriguez-Soca Y, Munteanu CR, Dorado J, et al. Plasmod-PPI: a web-server predicting complex biopolymer targets in Plasmodium with entropy measures of protein - protein interactions. Polymer 2010;51:264-273
107. Basak SC, Mills D, Hawkins DM, Bhattacharjee AK. Quantitative structure - activity relationship studies of antimalarial compounds from their calculated mathematical descriptors. SAR QSAR Environ Res 2010;21:103-125
108. Ojha PK, Roy K. Chemometric modelling of antimalarial activity of aryltriazolylhydroxamates. Mol Simul 2010; in press
109. Santos-Filho OA, Mishra RK, Hopfinger AJ. Free energy force field (FEFF) 3D-QSAR analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors. J Comput Aided Mol Des 2001;15:787-810
110. Parenti MD, Pacchioni S, Ferrari AM, Rastelli G. Three-dimensional quantitative structure - activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach. J Med Chem 2004;47:4258-4267
111. Hecht D, Cheung M, Fogel GB. QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives. BioSystems 2008;92:10-15
112. Fogel GB, Cheung M, Pittman E, Hecht D. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase. J Mol Graph Model 2008;26:1145-1152
113. Bhattacharjee AK, Geyer JA, Woodard CL, et al. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors. J Med Chem 2004;47:5418-5426
114. Desai PV, Patny A, Gut J, et al. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J Med Chem 2006;49:1576-1584
115. Franca TCC, Pascutti PG, Ramalho TC, Figueroa-Villar JD. A three-dimensional structure of Plasmodium falciparum serine hydroxymethyltransferase in complex with glycine and 5-formyl-tetrahydrofolate. Homology modeling and molecular dynamics. Biophys Chem 2005;115:1-10
116. Silber K, Heidler P, Kurz T, Klebe G. AFMoC Enhances Predictivity of 3D QSAR: A Case Study with DOXP-reductoisomerase. J Med Chem 2005;48:3547-3563
117. Fletcher S, Cummings CG, Rivas K, et al. Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure - activity relationships of ethylenediamine-analogue scaffolds and homology model validation. J Med Chem 2008;51:5176-5197
118. Gupta MK, Prabhakar YS. QSAR study on tetrahydroquinoline analogues as plasmodium protein farnesyltransferase inhibitors: a comparison of rationales of malarial and mammalian enzyme inhibitory activities for selectivity. Eur J Med Chem 2008:43:2751-2767
119. Mukherjee P, Pradhan A, Shah F, et al. Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): a novel target for the development of antimalarial therapy. Bioorg Med Chem 2008;16:5254-5265
120. Heikkila T, Thirumalairajan S, Davies M, et al. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett 2006;16:88-92
121. Heikkila T, Ramsey C, Davies M, et al. Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem 2007;50:186-191
122. Lee PJ, Bhonsle JB, Gaona HW, et al. Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents. J Med Chem 2009;52:952-963
123. Mohapatra SC, Tiwari HK, Singla M, et al. Antimalarial evaluation of copper (II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum. J Biol Inorg Chem 2010;15:373-385
124. Frecer V, Megnassan E, Miertus S. Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase. Eur J Med Chem 2009;44:3009-3019
125. Dheyongera JP, Geldenhuys WJ, Dekker TG, et al. Antimalarial activity of thioacridone compounds related to the acronycine alkaloid. Bioorg Med Chem 2005;13:1653-1659